Repare Therapeutics announces the acquisition of RP-3467, a Pol heta ATPase inhibitor, by Gilead Sciences for up to $30 million in total consideration.
The agreement includes a $25 million upfront payment and an additional $5 million payment upon completion of specified technology transfer activities.
The acquisition strengthens Repare's position in precision oncology and marks a significant milestone for the Company.
Strategic Acquisition
Gilead Sciences acquiring RP-3467 enhances its oncology research and development capabilities.
Total Consideration
Repare to receive up to $30 million, boosting the Company's financial position.
Portfolio Transaction
The Gilead Agreement is Repare's third and most significant portfolio transaction of the year.
- The upfront payment from Gilead has increased Repare's cash balance and revised the estimated cash payment per share for shareholders.
- RP-3467, a potent Pol heta ATPase inhibitor, holds promise in treating various cancers, including ovarian, breast, and prostate cancers.
With the acquisition of RP-3467 by Gilead Sciences, Repare Therapeutics is poised for further growth in the precision oncology sector.